‘A Needle in a Haystack’: How a New Study Could Revolutionize Parkinson’s Treatment

Wu Kaimin published a study in the journal Science which uncovered a therapeutic target and a potential drug candidate for Parkinson’s, a breakthrough that has been hailed as a major step toward finding a cure. Understanding Parkinson’s and the Need for New Treatments Parkinson’s is a progressive neurodegenerative disease that primarily affects people over 60. Early symptoms, such as a reduced sense of smell, sleep disturbances, and constipation, can precede the motor impairments, tremors, and muscle rigidity that define the disease. The condition worsens over decades, and current treatments only alleviate symptoms—there is no cure or therapy proven to slow its progression. With global Parkinson’s cases expected to rise from 8.5 million in 2019 to 13 million by 2040, the need for effective treatments is urgent. However, researchers have struggled to identify viable therapeutic targets, a key challenge in developing treatments that can slow or stop the disease. The Discovery: FAM171A2 and a Potential Drug Wu’s research revealed that FAM171A2 acts as a "gatekeeper," allowing toxic alpha-synuclein proteins to spread between neurons, a process believed to drive Parkinson’s progression. Using a library of over 7,000 chemical compounds, her team identified Bemcentinib, a drug that blocks this gate, potentially preventing the disease from spreading. The Challenges and Future Research Despite the breakthrough, Wu emphasizes that drug development is a long and uncertain process. Challenges include ensuring the drug can cross the blood-brain barrier, confirming its safety, and understanding the full function of FAM171A2 in a healthy body. Further research is needed to refine the treatment and test its effectiveness in animal models and clinical trials. Additionally, FAM171A2 is linked not just to Parkinson’s but also to Alzheimer’s disease and frontotemporal dementia, suggesting that Wu’s findings could influence research into multiple neurodegenerative conditions. A Long Road Ahead While her research has generated excitement, Wu remains cautious. She acknowledges that there are still many unknowns and that further studies are essential before this discovery can translate into a treatment. However, her work marks a significant step forward, offering new hope in the fight against Parkinson’s and other neurodegenerative diseases.